Cencora, Inc. (NYSE:COR) Stake Boosted by Natixis Advisors LLC

Natixis Advisors LLC increased its position in shares of Cencora, Inc. (NYSE:COR) by 3.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,028 shares of the company’s stock after acquiring an additional 5,198 shares during the period. Natixis Advisors LLC owned about 0.07% of Cencora worth $31,292,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. New Millennium Group LLC purchased a new stake in shares of Cencora during the 2nd quarter worth about $26,000. TFO Wealth Partners LLC acquired a new stake in Cencora in the first quarter valued at approximately $30,000. MFA Wealth Advisors LLC acquired a new stake in Cencora in the second quarter valued at approximately $30,000. Concord Wealth Partners bought a new stake in Cencora in the third quarter worth approximately $30,000. Finally, LRI Investments LLC acquired a new position in shares of Cencora during the 1st quarter worth $31,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling

In other news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the sale, the chairman now owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. This trade represents a 7.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 15.80% of the stock is owned by company insiders.

Cencora Price Performance

NYSE:COR opened at $240.24 on Monday. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. Cencora, Inc. has a one year low of $194.23 and a one year high of $251.56. The company has a fifty day moving average price of $232.62 and a 200 day moving average price of $231.03. The stock has a market cap of $47.34 billion, a P/E ratio of 31.99, a PEG ratio of 1.60 and a beta of 0.44.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be given a dividend of $0.55 per share. The ex-dividend date is Friday, November 15th. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a yield of 0.92%. Cencora’s dividend payout ratio (DPR) is 27.16%.

Analyst Upgrades and Downgrades

COR has been the subject of several analyst reports. Evercore ISI lifted their price objective on shares of Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Barclays boosted their price target on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Leerink Partners lowered their price objective on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Finally, UBS Group increased their price target on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $271.20.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.